Logo-jcvtr

J Cardiovasc Thorac Res. 2017;9(4): 191-195. doi: 10.15171/jcvtr.2017.33
PMID: 29391931        PMCID: PMC5787330

Original Article

In vitro inhibition of platelets aggregation with generic form of clopidogrel versus branded in patients with stable angina pectoris

Rza Hajizadeh 1, Samad Ghaffari 1, Mojtaba Ziaee 2 * , Behrooz Shokouhi 1, Ahmad Separham 1, Parvin Sarbakhsh 1

Cited by CrossRef: 3


1- Leclerc J, Thibault M, Midiani Gonella J, Beaudoin C, Sampalis J. Are Generic Drugs Used in Cardiology as Effective and Safe as their Brand-name Counterparts? A Systematic Review and Meta-analysis. Drugs. 2020;80(7):697 [Crossref]
2- Rustomyan A, Kondrashin S, Fomin V. Therapy with original and generic forms of clopidogrel after implantation of Russian drug-eluting coronary stents. Rus Cardio Bull. 2024;19(2):62 [Crossref]
3- Sicras-Mainar A, Escobar-Cervantes C, Micó-Pérez R, Llisterri-Caro J. Consecuencias clínicas y económicas en pacientes que inician tratamiento con clopidogrel de marca vs. genérico: estudio retrospectivo de vida real. Medicina de Familia SEMERGEN. 2020;46(1):16 [Crossref]
4- Chan C, Tung Y, Lee K, Chan Y, Chu P. Clinical outcomes of generic versus brand‐name clopidogrel for secondary prevention in patients with acute myocardial infarction: A nationwide cohort study. Clinical Translational Sci. 2023;16(9):1594 [Crossref]
5- Zhang J, Sun Y, He J, Wu G, Wang R, Zhang J. Comprehensive Investigation of the Influence of High-Altitude Hypoxia on Clopidogrel Metabolism and Gut Microbiota. CDM. 2023;24(10):723 [Crossref]